BILBREY JOHN P
BILBREY JOHN P's purchase track record
BILBREY JOHN P has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/11/2022 | ELAN | $99K | -4.6% | -36.6% | +3.3% |
| 5/11/2022 | ELAN | $220K | -6.2% | -42.1% | -4.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Elanco (ELAN) Highlighted in Mid-Cap Stock Watchlist. Elanco was included in a recent Yahoo Finance article listing mid-cap stocks to monitor. The company is currently trading near its 52-week low, with an RSI of 38.5 indicating potential oversold conditions. Analysts maintain an average price target of $31.00, which is higher than the current trading level.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
LVMH Q3 China Slowdown; Kate Spade Targets Gen Z. LVMH reported that its Fashion & Leather Goods division saw organic sales decline by 5% in Q3, citing a demand slowdown in China. This macro headwind is relevant to Tapestry, which also operates in the luxury sector. Meanwhile, Kate Spade CEO Eva Erdmann is focusing on the brand's heritage to attract younger Gen Z customers.
Transaction History
| CL | ▲ Buy | Grant | 265 | $24K | 7/1/2026 | View on chart |
| CL | ▲ Buy | Grant | 2,075 | $0 | 5/11/2026 | View on chart |
| CL | ▲ Buy | Grant | 266 | $24K | 4/1/2026 | View on chart |
| CL | ▲ Buy | Grant | 301 | $24K | 1/2/2026 | View on chart |
| CL | ▲ Buy | Grant | 289 | $24K | 10/1/2025 | View on chart |
| CL | ▲ Buy | Grant | 264 | $24K | 7/1/2025 | View on chart |
| CL | ▲ Buy | Grant | 2,019 | $0 | 5/12/2025 | View on chart |
| CL | ▲ Buy | Grant | 231 | $21K | 4/1/2025 | View on chart |
| CL | ▲ Buy | Grant | 228 | $21K | 1/2/2025 | View on chart |
| ELAN | ▲ Buy | Grant | 18,169 | $0 | 11/29/2024 | View on chart |
| TPR | ▲ Buy | Grant | 3,459 | $200K | 11/14/2024 | View on chart |
| CL | ▲ Buy | Grant | 201 | $21K | 10/1/2024 | View on chart |
| CL | ▲ Buy | Grant | 222 | $21K | 7/1/2024 | View on chart |
| CL | ▲ Buy | Grant | 1,905 | $0 | 5/13/2024 | View on chart |
| CL | ▲ Buy | Option Exercise | 6,329 | $393K | 5/1/2024 | View on chart |
| CL | ▼ Sell | Open Market | 6,329 | $580K | 5/1/2024 | View on chart |
| CL | ▲ Buy | Grant | 240 | $21K | 4/1/2024 | View on chart |
| CL | ▲ Buy | Grant | 271 | $21K | 1/2/2024 | View on chart |
| ELAN | ▲ Buy | Grant | 20,374 | $0 | 11/30/2023 | View on chart |
| TPR | ▲ Buy | Grant | 3,110 | $85K | 11/2/2023 | View on chart |
| CL | ▲ Buy | Grant | 292 | $21K | 10/2/2023 | View on chart |
| CL | ▲ Buy | Grant | 278 | $21K | 7/3/2023 | View on chart |
| CL | ▲ Buy | Grant | 2,220 | $0 | 5/15/2023 | View on chart |
| CL | ▲ Buy | Option Exercise | 5,703 | $409K | 5/9/2023 | View on chart |
| CL | ▼ Sell | Open Market | 5,703 | $461K | 5/9/2023 | View on chart |
| CL | ▲ Buy | Grant | 291 | $21K | 4/3/2023 | View on chart |
| CL | ▲ Buy | Grant | 271 | $21K | 1/3/2023 | View on chart |
| ELAN | ▲ Buy | Grant | 18,649 | $0 | 11/30/2022 | View on chart |
| TPR | ▲ Buy | Grant | 2,430 | $85K | 11/15/2022 | View on chart |
| ELAN | ▲ Buy | Open Market | 7,500 | $99K | 11/11/2022 | View on chart |
| CL | ▲ Buy | Grant | 280 | $21K | 10/3/2022 | View on chart |
| CL | ▲ Buy | Grant | 273 | $21K | 7/1/2022 | View on chart |
| ELAN | ▲ Buy | Open Market | 10,000 | $220K | 5/11/2022 | View on chart |
| CL | ▲ Buy | Grant | 2,317 | $0 | 5/9/2022 | View on chart |
| CL | ▲ Buy | Grant | 283 | $21K | 4/1/2022 | View on chart |
| CL | ▲ Buy | Option Exercise | 5,389 | $387K | 2/14/2022 | View on chart |
| CL | ▼ Sell | Open Market | 4,917 | $387K | 2/14/2022 | View on chart |
| CL | ▲ Buy | Grant | 262 | $21K | 1/3/2022 | View on chart |
| ELAN | ▲ Buy | Grant | 7,307 | $0 | 11/30/2021 | View on chart |
| TPR | ▲ Buy | Grant | 1,793 | $75K | 11/3/2021 | View on chart |
| CL | ▲ Buy | Grant | 276 | $21K | 10/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Colgate-Palmolive dividend focus ahead of Q3 earnings call
Recent coverage lists Colgate‑Palmolive as a dividend champion and a contender for income‑focused investors. The company will host its 2026 third‑quarter earnings webcast on October 30, where results and guidance are expected. Investors noting the upcoming November 13 dividend should be aware of the October 20 record date to qualify for the payment. The stock continues to trade with a dividend yield of about 2.5%.
Colgate-Palmolive dividend focus ahead of Q3 earnings call. Recent coverage lists Colgate‑Palmolive as a dividend champion and a contender for income‑focused investors. The company will host its 2026 third‑quarter earnings webcast on October 30, where results and guidance are expected. Investors noting the upcoming November 13 dividend should be aware of the October 20 record date to qualify for the payment. The stock continues to trade with a dividend yield of about 2.5%.